Current Addiction Reports
September 8, 2023
Anna Ross, Jake Hawthorn
Abstract Purpose of Review The use of certain illicit substances as a form of therapy, and particularly as an adjunct to psychotherapy, has gained increasing media and academic attention over the last decade, culminating in what has been coined “the psychedelic renaissance.” This section in Current Addiction Reports has been developed in order to highlight the new and emerging research around...
Berkeley Undergraduate Journal
September 7, 2023
Dylan Earp
There has been an emergence in psychedelic science in recent years, in both basic and applied research. Clinical trials have shown psychedelic drugs to be exceptionally effective in treating psychiatric illnesses such as post-traumatic stress disorder (PTSD) and depression, while other research suggests they may be effective in treating a range of other indications in the future. Outside of the...
Cannabis and Cannabinoid Research
September 2023
Bryan W. Jenkins, Catherine F Moore, Dan P Covey et al.
Background: Cannabis and its primary psychoactive constituent delta-9-tetrahydrocannabinol (D9-THC) produce biphasic, dose-dependent effects on anxiety. In addition to D9-THC, cannabis contains other "minor" cannabinoids and terpenes with purported therapeutic potential for the treatment of anxiety. Empirical data on potential therapeutic effects of these compounds is limited. The current study...
Mindfulness
September 1, 2023
Blair T Johnson, Rebecca L. Acabchuk, Elisabeth A George et al.
45 citations
Universities increasingly offer mindfulness-based programs (MBPs) to improve student health and reduce their impact on overburdened psychological services. It is critical for evidence-based policy to determine for what health outcomes mindfulness programs are effective and under what conditions. Objectives were to: (a) perform a comprehensive analysis of the effects of mindfulness interventions...
Journal of Psychoactive Drugs
August 31, 2023
Haley Maria Dourron, Heith Copes, Agasthya Vedre-Kyanam et al.
6 citations
Deliriants are the least studied class of hallucinogens and display noticeable subjective effects, including dysphoria, hallucinations, and substantial alterations in thought. High doses of diphenhydramine (DPH), an over-the-counter antihistamine medication, can produce deliriant effects due to secondary anticholinergic activity. We sought to characterize the subjective experiences produced by...
JAMA
August 31, 2023
Rachel Yehuda, Amy Lehrner
33 citations
An increasing number of clinicians and researchers have become interested in the potential of psychedelic drugs for the treatment of mental health disorders, including depression, anxiety, posttraumatic stress disorder, eating disorders, and addictions.1,2
Journal of Psychopharmacology
August 31, 2023
Pravesh Sharma, Quang Anh Nguyen, Erin Carpenter et al.
32 citations
Hallucinogenic mushrooms have been used in religious and cultural ceremonies for centuries. Of late, psilocybin, the psychoactive compound in hallucinogenic mushrooms, has received increased public interest as a novel drug for treating mood and substance use disorders (SUDs). In addition, in recent years, some states in the United States have legalized psilocybin for medical and recreational...
Journal of Applied Toxicology
August 30, 2023
Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet et al.
2 citations
Abstract Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5‐methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. Clinical trials with psilocybin and LSD have shown improvement in emotional and psychological scores. Although these...
Health Psychology
August 24, 2023
Shoushi Wang, Chunyang Zhang, Wei Xu
Objectives: Due to the population aging, there is an urgent need to focus on how to help the oldest old (people age 80 years or older) to reach successful aging and improve their life quality. In this study, a longitudinal design spanning 1 year was used to explore the relationship between trait mindfulness and the physical and mental health of the oldest old and the mediating role of attitude...
Journal of Psychoactive Drugs
August 24, 2023
Stanley Wong, An Yi Yu, Nicholas Fabiano et al.
11 citations
There has been a resurgence of interest in the use of psychedelic therapies for several mental and substance use disorders. Psilocybin, a "classic" serotonergic psychedelic, has emerged as one of the primary compounds of interest in clinical research. While research on psilocybin's potential mental health benefits has grown, data on the safety and efficacy of other serotonergic psychedelics...